A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Trial Profile

A Phase 2 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2015

At a glance

  • Drugs Masitinib (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors AB Science
  • Most Recent Events

    • 26 Sep 2015 Status changed from completed to discontinued. This study was terminated due to lack of efficacy according to the results published in Annals of Oncology.
    • 20 Dec 2013 Status changed from active, no longer recruiting to completed, based on information in an EMA report.
    • 04 Oct 2012 Results from this trial supported a Marketing Authorisation Application in the EU for masitinib to treat gastrointestinal stromal tumours.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top